down arrow

Unicycive Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: US90466Y1038
USD
6.50
0.64 (10.92%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.146.55

52 Week

3.7111.00
Valuation
Technical
Day's Volume

CASH

307.81 k

Shareholding (Mar 2025)

FII

1.64%

Held by 4 FIIs

DII

85.6%

Held by 9 DIIs

Promoter

10.95%

How big is Unicycive Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Unicycive Therapeutics, Inc. has a market capitalization of 82.84 million, with net sales of 0.00 million and a net profit of -21.18 million over the last four quarters. The company's shareholder's funds are 7.43 million, and total assets are 31.67 million.

Market Cap: As of Jun 18, Unicycive Therapeutics, Inc. has a market capitalization of 82.84 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Unicycive Therapeutics reported net sales of 0.00 million and a net profit of -21.18 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 7.43 million, while total assets were reported at 31.67 million.

Read More

What does Unicycive Therapeutics, Inc. do?

22-Jun-2025

Unicycive Therapeutics, Inc. is a micro-cap company in the miscellaneous industry, recently reporting a net profit of $1 million for Q1 2025, with a market cap of $82.84 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -315.28%.

Overview:<BR>Unicycive Therapeutics, Inc. operates in the miscellaneous industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: 1 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 82.84 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.71 <BR>Return on Equity: -315.28% <BR>Price to Book: 7.35<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Unicycive Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 14, 2023, Unicycive Therapeutics, Inc. is considered overvalued with a valuation downgrade to "does not qualify," reflected by a Price to Book Value of 8.07, a negative EV to EBIT of -2.32, and a concerning ROE of -315.28%, indicating severe operational inefficiencies compared to its peers.

As of 14 November 2023, Unicycive Therapeutics, Inc. has moved from a valuation grade of risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued given its financial metrics, including a Price to Book Value of 8.07 and a negative EV to EBIT of -2.32. The return on equity (ROE) is alarmingly low at -315.28%, reflecting severe operational inefficiencies.<BR><BR>In comparison to its peers, Unicycive's valuation metrics are concerning. For instance, Gaia, Inc. has a P/E ratio of -21.71 and an EV to EBITDA of 9.03, while Coya Therapeutics, Inc. shows a P/E of -5.19 and an EV to EBITDA of -2.75. These figures suggest that Unicycive is not only underperforming but is also mispriced relative to its industry. Despite its recent stock performance, which has significantly outpaced the S&P 500 over various periods, the underlying financial health of the company does not support its current valuation, reinforcing the conclusion that it is overvalued.

Read More

Is Unicycive Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 18, 2025, Unicycive Therapeutics, Inc. shows a mildly bullish trend overall, with mixed signals from technical indicators and a year-to-date performance of -48.5% compared to the S&P 500's 12.22%, although it has a positive 1-year return of 4.18%.

As of 18 August 2025, the technical trend for Unicycive Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a monthly MACD that is mildly bullish, despite a bearish weekly MACD. The moving averages indicate a bearish trend on the daily timeframe, while the weekly and monthly KST are mildly bullish. However, the Bollinger Bands and Dow Theory show a mildly bearish stance on both weekly and monthly timeframes. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 year-to-date with a return of -48.5% compared to the S&P 500's 12.22%, but has a positive 1-year return of 4.18% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 77 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.33

stock-summary
Return on Equity

-179.41%

stock-summary
Price to Book

4.70

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
51.52%
0%
51.52%
6 Months
-14.81%
0%
-14.81%
1 Year
-8.72%
0%
-8.72%
2 Years
32.65%
0%
32.65%
3 Years
828.57%
0%
828.57%
4 Years
-64.09%
0%
-64.09%
5 Years
0%
0%
0.0%

Unicycive Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Unicycive Therapeutics, Inc. technically bullish or bearish?

As of 18 August 2025, the technical trend for Unicycive Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a monthly MACD that is mildly bullish, despite a bearish weekly MACD. The moving averages indicate a bearish trend on the daily timeframe, while the weekly and monthly KST are mildly bullish. However, the Bollinger Bands and Dow Theory show a mildly bearish stance on both weekly and monthly timeframes. In terms of performance, the stock has underperformed the S&P 500 year-to-date with a return of -48.5% compared to the S&P 500's 12.22%, but has a positive 1-year return of 4.18% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-77.60%
EBIT Growth (5y)
-53.04%
EBIT to Interest (avg)
-28.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.71
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
67.11%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.07
EV to EBIT
-2.32
EV to EBITDA
-2.35
EV to Capital Employed
-9.03
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-315.28%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (1.8%)

Foreign Institutions

Held by 4 Foreign Institutions (1.64%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -1,380.00% vs 102.33% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.80",
          "val2": "-7.90",
          "chgp": "13.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "8.30",
          "chgp": "-95.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.40",
          "val2": "0.50",
          "chgp": "-1,380.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -30.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -20.33% vs -68.51% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.70",
          "val2": "-20.50",
          "chgp": "-54.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.80",
          "val2": "-10.30",
          "chgp": "43.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.70",
          "val2": "-30.50",
          "chgp": "-20.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-30,776.30%",
          "chgp": "3,077.63%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.80
-7.90
13.92%
Interest
0.00
0.00
Exceptional Items
0.40
8.30
-95.18%
Consolidate Net Profit
-6.40
0.50
-1,380.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -1,380.00% vs 102.33% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.70
-100.00%
Operating Profit (PBDIT) excl Other Income
-31.70
-20.50
-54.63%
Interest
0.10
0.10
Exceptional Items
-5.80
-10.30
43.69%
Consolidate Net Profit
-36.70
-30.50
-20.33%
Operating Profit Margin (Excl OI)
0.00%
-30,776.30%
3,077.63%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -30.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -20.33% vs -68.51% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Unicycive Therapeutics, Inc. stock-summary
stock-summary
Unicycive Therapeutics, Inc.
Miscellaneous
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."